Cargando…
A Critical Analysis of the Clinical Use of Incretin-Based Therapies : Are the GLP-1 therapies safe?
There is no question that incretin-based glucose-lowering medications have proven to be effective glucose-lowering agents. Glucagon-like peptide 1 (GLP-1) receptor agonists demonstrate an efficacy comparable to insulin treatment and appear to do so with significant effects to promote weight loss wit...
Autores principales: | Butler, Peter C., Elashoff, Michael, Elashoff, Robert, Gale, Edwin A.M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687282/ https://www.ncbi.nlm.nih.gov/pubmed/23645885 http://dx.doi.org/10.2337/dc12-2713 |
Ejemplares similares
-
A Critical Analysis of the Clinical Use of Incretin-Based Therapies: The benefits by far outweigh the potential risks
por: Nauck, Michael A.
Publicado: (2013) -
Is Incretin-Based Therapy Ready for the Care of Hospitalized Patients With Type 2 Diabetes?: The time has come for GLP-1 receptor agonists!
por: Schwartz, Stanley, et al.
Publicado: (2013) -
Is Incretin-Based Therapy Ready for the Care of Hospitalized Patients With Type 2 Diabetes?: Insulin therapy has proven itself and is considered the mainstay of treatment
por: Umpierrez, Guillermo E., et al.
Publicado: (2013) -
Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm
por: Abdul-Ghani, Muhammad, et al.
Publicado: (2017) -
2012 ESC STEMI guidelines and reperfusion therapy: Evidence base ignored, threatening optimal patient management
por: Terkelsen, Christian Juhl, et al.
Publicado: (2013)